Streetbeat News

ESALY

Eisai Co Ltd

https://www.eisai.co.jp/

CEO

Haruo Naito

Industry

Pharmaceutical Preparation Manufacturing

Open

62.35

Mkt cap

18B

Volume

332K

High

63.29

P/E Ratio

20.54

52-wk high

73.90

Low

61.00

Div yield

N/A

52-wk low

36.88

Eli Lilly plans to invest $294.41 million in a new Gateway Lab in the U.K., enhancing its presence in the life sciences sector. However, its Alzheimer's drug, donanemab, faces regulatory challenges in Europe due to safety concerns. The European Medicines Agency has been cautious, having already rejected a similar drug by Biogen and Eisai. The U.K. is reviewing donanemab, but challenges remain due to the cost and complexity of early Alzheimer's diagnosis.

Portfolio Pulse from Vandana Singh

October 14, 2024 | 5:52 pm

Biogen's Alzheimer's drug Leqembi, developed with Eisai, offers hope for early-stage Alzheimer's patients by slowing cognitive decline. Despite logistical challenges and side effects, sales have grown since its approval. Biogen is working on making the treatment more accessible.

Portfolio Pulse from Vandana Singh

September 09, 2024 | 2:12 pm

Biogen and Eisai's Alzheimer's drug Leqembi received a negative opinion from the European Medicines Agency's advisory panel due to serious side effects. This decision impacts Biogen's stock, which fell by 6.11%. Eisai plans to seek re-examination of the decision.

Portfolio Pulse from Vandana Singh

July 26, 2024 | 2:21 pm

Leqembi, an Alzheimer's drug developed by Eisai Limited (OTC:ESALY) and Biogen Inc (NASDAQ:BIIB), is experiencing slow adoption nine months post-U.S. launch due to skepticism among doctors about its efficacy, costs, and risks. Despite FDA approval and showing a 27% slowdown in cognition decline, less than half of U.S. neurologists recommend it, citing limited patient benefit and significant risks, including potential brain swelling and bleeding. The drug's high cost and the need for regular MRIs and bi-monthly infusions add to the concerns. Eisai and Biogen aim to increase their sales force by 30% to reach 100,000 patients by 2026, despite only a couple thousand patients starting treatment as of January.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 6:23 pm

The European Medicines Agency (EMA) has postponed the Oral Explanation for Biogen Inc and Eisai Co Ltd's Alzheimer's drug, Lecanemab, due to procedural issues. This delay affects the drug's review process, initially expected to conclude by June 30, 2024. The postponement follows a recent court ruling impacting EMA's policy on managing conflicts of interest among its Scientific Advisory Groups. Despite the delay, an approval is still anticipated in the second half of 2024. BIIB shares dropped 1.10% following the news.

Portfolio Pulse from Vandana Singh

March 22, 2024 | 5:44 pm

The FDA has delayed its decision on Eli Lilly's Alzheimer's drug, donanemab, pending further review, causing Eli Lilly's stock to drop and Biogen's stock to rise due to the delay benefiting Biogen's competing drug, Leqembi.

Portfolio Pulse from Vandana Singh

March 08, 2024 | 1:58 pm

Biogen Inc (NASDAQ:BIIB) reported Q4 2023 sales of $2.39 billion, missing estimates and showing a 6% Y/Y decline. Adjusted EPS also fell by 27%. The company's partner, Eisai Co Ltd (OTC:ESALY), faces delays with Leqembi's patient enrollment, impacting Biogen's stock growth. Baird analyst lowered Biogen's price target to $316 from $333 but maintained an Outperform rating. Competition in Spinal Muscular Atrophy treatments from Novartis AG (NYSE:NVS) and Roche's Genentech affects Biogen's Spinraza. Biogen may pursue $1B-$2B deals to fill revenue gaps, focusing on the CNS space.

Portfolio Pulse from Vandana Singh

February 14, 2024 | 8:11 pm

Blood tests for Alzheimer's diagnosis are gaining momentum, with Quest Diagnostics and LabCorp offering consumer-available tests. However, concerns about accuracy persist as none have FDA approval. The FDA is considering stricter regulations. Meanwhile, drugs like Biogen/Eisai's Leqembi and Eli Lilly's donanemab highlight the need for precise diagnosis. Medicare revised its policy on amyloid PET scans, and new NIH-funded research shows promise for early detection.

Portfolio Pulse from Vandana Singh

January 12, 2024 | 6:17 pm

Merck & Co Inc (MRK) and Eisai Co Ltd (ESALY, ESALF) announced the Phase 3 LEAP-001 trial of Keytruda plus Lenvima did not meet primary endpoints for treating advanced or recurrent endometrial carcinoma. This follows previous trial failures in lung cancer and melanoma. However, a trial in renal cell carcinoma showed a benefit. MRK shares saw a slight premarket increase.

Portfolio Pulse from Vandana Singh

December 08, 2023 | 1:26 pm

Blood tests for diagnosing Alzheimer's disease are in development but not yet approved by regulators or insurance reimbursement. Eisai Co Ltd's and Biogen Inc's new Alzheimer's drug, Leqembi, currently relies on cognitive assessments or invasive cerebrospinal fluid tests. Laboratory Corporation Of America Holdings and Quest Diagnostics Incorporated have introduced blood tests measuring amyloid, tau, and neurodegeneration. Eli Lilly And Co is working with Quanterix on an experimental tau biomarker blood test and has partnered with Roche Holdings AG to develop a test measuring blood levels of a different tau protein and a gene associated with Alzheimer's risk.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 6:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.